| KALVISTA PHARMACEUTICALS |
| USA |
| Gesundheit |
| US4834971032 / A2DG49 |
| 4XC1 (Frankfurt) / KALV (NASDAQ) |
| FRA:4XC1, ETR:4XC1, 4XC1:GR, NASDAQ:KALV |
| - |
| https://www.kalvista.com/ |
|
KalVista Pharmaceuticals Inc. is a clinical-stage ..
>Volltext.. |
| 677.07 Mio. EUR |
| 654.37 Mio. EUR |
| 1.22 Mio. EUR |
| -172.63 Mio. EUR |
| -173.72 Mio. EUR |
| -3.42 EUR |
| 241.71 Mio. EUR |
| 208.28 Mio. EUR |
| -143.01 Mio. EUR |
| 6.86 |
| - |
| -35.86% |
| - |
| - |
| - |
| - |
| KALVISTA |
| 10.01.26 |